The resulting pain is the main symptom of acute pancreatitis and it should be alleviated as soon as possible. NSAIDs are the first line therapy for pain and they are generally administered to acute pancreatitis patients upon admission to the hospital. In addition, these drugs have also been used to prevent post-endoscopic cholangiopancreatography (ERCP) acute pancreatitis. On the other hand, there are several reports indicating that NSAIDs may be the actual cause of acute pancreatitis. We carried out a literature search on PubMed/MEDLINE; all full text papers published in from January 1966 to November 2009 on the use of NSAIDs in acute pancreatitis were collected; the literature search was also supplemented by a review of the bibliographies of the papers evaluated. Thus, in this article, we will systematically review the current literature in order to better illustrate the role of NSAIDs in acute pancreatitis, in particular: i) NSAIDs as a cause of acute pancreatitis; ii) their use to prevent post-retrograde ERCP pancreatitis and iii) their efficacy for pain relief in the acute illness of the pancreas.
References
[1]
Ebbehoj, N.; Friis, J.; Svendsen, L.B.; Bulow, S.; Madsen, P. Indomethacin treatment of acute pancreatitis. A controlled double-blind trial. Scand. J. Gastroenterol.？1985, 20, 798–800, doi:10.3109/00365528509088825. 2413519
[2]
Jakobs, R.; Adamek, M.U.; von Bubnoff, A.C.; Riemann, J.F. Buprenorphine or procaine for pain relief in acute pancreatitis. A prospective randomized study. Scand. J. Gastroenterol.？2000, 35, 1319–1323, doi:10.1080/003655200453692. 11199374
[3]
Stevens, M.; Esler, R.; Asher, G. Transdermal fentanyl for the management of acute pancreatitis pain. Appl. Nurs. Res.？2002, 15, 102–110.
[4]
Kahl, S.; Zimmermann, S.; Pross, M.; Schulz, H.U.; Schmidt, U.; Malfertheiner, P. Procaine hydrochloride fails to relieve pain in patients with acute pancreatitis. Digestion？2004, 69, 5–9.
[5]
Mennecier, D.; Ceppa, F.; Sinayoko, L.; Corberand, D.; Harnois, F.; Thiolet, C.; Farret, O. Acute pancreatitis after treatment by celecoxib. Gastroenterol. Clin. Biol.？2007, 31, 668–669.
Maroy, B. Benign acute pancreatitis probably due to taking ketoprofen. Therapie？1998, 53, 602–603.
[9]
Flamenbaum, M.; Abergel, A.; Marcato, N.; Zenut, M.; Kemeny, J.L.; Cassan, P. Regressive fulminant hepatitis, acute pancreatitis and renal insufficiency after taking ketoprofen. Gastroenterol. Clin. Biol.？1998, 22, 975–976. 9881281
[10]
Aygencel, G.; Akbuga, B.; Keles, A. Acute pancreatitis following naproxen intake. Eur. J. Emerg. Med.？2006, 13, 372.
[11]
Mahjoub, W.; Jarboui, S.; Ben Moussa, M.; Abdesselem, M.M.; Zaouche, A. Indomethacin-induced pancreatitis: A second case report. JOP？2006, 7, 321–323.
[12]
Memis, D.; Akalin, E.; Yucel, T. Indomethacin-induced pancreatitis: A case report. JOP？2005, 6, 344–347.
[13]
Nind, G.; Selby, W. Acute pancreatitis: A rare complication of celecoxib. Intern. Med. J.？2002, 32, 624–625.
[14]
Amaravadi, R.K.; Jacobson, B.C.; Solomon, D.H.; Fischer, M.A. Acute pancreatitis associated with rofecoxib. Am. J. Gastroenterol.？2002, 97, 1077–1078.
[15]
Baciewicz, A.M.; Sokos, D.R.; King, T.J. Acute pancreatitis associated with celecoxib. Ann. Intern. Med.？2000, 132, 680.
[16]
Carrillo-Jimenez, R.; Nurnberger, M. Celecoxib-induced acute pancreatitis and hepatitis: A case report. Arch. Intern. Med.？2000, 160, 553–554.
[17]
Castiella, A.; Lopez, P.; Bujanda, L.; Arenas, J.I. Possible association of acute pancreatitis with naproxen. J. Clin. Gastroenterol.？1995, 21, 258.
[18]
Murray, B.; Carter, R.; Imrie, C.; Evans, S.; O'Suilleabhain, C. Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography. Gastroenterology？2003, 124, 1786–1791.
[19]
Kim, K.H.; Kim, T.N.; Jang, B.I. A case of acute pancreatitis caused by 5-aminosalicylic acid suppositories in a patient with ulcerative colitis. Korean J. Gastroenterol.？2007, 50, 379–383.
[20]
Montano Loza, A.; Garcia Correa, J.; Gonzalez Ojeda, A.; Fuentes Orozco, C.; Davalos Cobian, C.; Rodriguez Lomeli, X. Prevention of hyperamilasemia and pancreatitis after endoscopic retrograde cholangiopancreatography with rectal administration of indomethacin. Rev. Gastroenterol. Mex.？2006, 71, 262–267.
[21]
Vlasov, A.I.; Berezin, V.A.; Gerasimenko, A.V.; Mosina, L.M.; Saushev, I.V. Dimephosphon in complex therapy of acute edematous pancreatitis. Vestn. Khir. Im. I. I. Grek.？2003, 162, 81–84.
[22]
Bulychev, V.F.; Vakhrushev, Ia.M. Therapy of patients with chronic pancreatitis of alcoholic etiology by dalagrin and laser therapy of the blood. Klin. Med. (Mosk)？2000, 78, 43–45.
[23]
Schworer, H.; Ramadori, G. Acute pancreatitis--adverse effect of 5-aminosalicylic acid (mesalazine) in various galenic dosage forms. Dtsch. Med. Wochenschr.？2000, 125, 1328–1330.
[24]
Glintborg, B. Pancreatitis in a patient with Crohn disease treated with mesalazine and azathioprine. Ugeskr. Laeger.？2000, 162, 4553–4554.
[25]
Miyasaka, Y.; Ono, K.; Nagayama, K.; Murakami, T.; Noguchi, O.; Uchihara, M.; Izumi, N.; Miyake, S.; Kubota, K.; Enomoto, N.; Tanaka, Y.; Marumo, F.; Sato, C. A case of pancreatic pleural effusion and ascites treated successfully with conservative measures including octreotide and nafamostat mesilate. Nippon Shokakibyo Gakkai Zasshi？1996, 93, 937–941.
[26]
Skomarovskii, A.T.; Zemskov, V.S.; Skomarovskii, A.A. Use of dalargin in the treatment of acute cholecystopancreatitis complicated by obstructive jaundice. Klin. Khir.？1996, 8, 13–14.
[27]
Zheng, M.H.; Xia, H.H.; Chen, Y.P. Rectal administration of NSAIDs in the prevention of post-ERCP pancreatitis: A complementary meta-analysis. Gut？2008, 57, 1632–1633.
[28]
Lankisch, P.G. Indomethacin may reduce the incidence and severity of acute pancreatitis after ERCP. Am. J. Gastroenterol.？2008, 103, 244.
[29]
Bai, Y.; Duowu, Z.; Zhaoshen, L. Is indomethacin a new hope for post-ERCP pancreatitis? Am. J. Gastroenterol.？2007, 102, 2103. 17727438
[30]
Wagh, M.S.; Sherman, S. Indomethacin for post-ERCP pancreatitis prophylaxis: Another attempt at the Holy Grail. Am. J. Gastroenterol.？2007, 102, 984–986.
[31]
Antonopoulos, S.; Mikros, S.; Kokkoris, S.; Protopsaltis, J.; Filioti, K.; Karamanolis, D.; Giannoulis, G. A case of acute pancreatitis possibly associated with combined salicylate and simvastatin treatment. JOP？2005, 6, 264–268.
[32]
Boix, E.; Lopez, P.; Perez-Mateo, M.; Pico, A. Lanreotide autogel is a therapeutic option for patients who develop acute pancreatitis after somatostatin analog treatment. J. Endocrinol. Invest.？2004, 27, 613–614.
[33]
Machala, W.; Wachowicz, N.; Komorowska, A.; Gaszynski, W. The use of drotrecogin alfa (activated) in severe sepsis during acute pancreatitis - two case studies. Med. Sci. Monit.？2004, 10, CS31–CS36.
[34]
Oiofinlade, O. Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography. Gastroenterology？2004, 126, 632.
Toubanakis, C.; Batziou, E.; Sipsas, N.; Galanopoulos, G.; Tzivras, M.; Archimandritis, A. Acute pancreatitis after long-term therapy with mesalazine, and hyperamylasaemia associated with azathioprine in a patient with ulcerative colitis. Eur. J. Gastroenterol. Hepatol.？2003, 15, 933–934.
[37]
Freeman, M.L. Prevention of post-ERCP pancreatitis: Pharmacologic solution or patient selection and pancreatic stents? Gastroenterology？2003, 124, 1977–1980, doi:10.1016/S0016-5085(03)00553-5. 12806633
[38]
Famularo, G.; Bizzarri, C.; Nicotra, G.C. Acute pancreatitis caused by ketorolac tromethamine. J. Clin. Gastroenterol.？2002, 34, 283–284.
[39]
Yang, C.C.; Deng, J.F.; Lin, T.J. Pancytopenia, hyperglycemia, shock, coma, rhabdomyolysis, and pancreatitis associated with acetaminophen poisoning. Vet. Hum. Toxicol.？2001, 43, 344–347. 11757993
[40]
Adachi, E.; Okazaki, K.; Matsushima, Y.; Seno, H.; Uchida, K.; Nakase, H.; Kawanami, C.; Nakamura, T.; Chiba, T. Acute pancreatitis secondary to 5-aminosalicylic acid therapy in a patient with ulcerative colitis. Int. J. Pancreatol.？1999, 25, 217–221.
[41]
Fernandez, J.; Sala, M.; Panes, J.; Feu, F.; Navarro, S.; Teres, J. Acute pancreatitis after long-term 5-aminosalicylic acid therapy. Am. J. Gastroenterol.？1997, 92, 2302–2303.
[42]
Debongnie, J.C.; Dekoninck, X. Sulfasalazine, 5-ASA and acute pancreatitis in Crohn's disease. J. Clin. Gastroenterol.？1994, 19, 348–349.
[43]
Choi, C.W.; Kang, D.H.; Kim, G.H.; Eum, J.S.; Lee, S.M.; Song, G.A.; Kim, D.U.; Kim, I.D.; Cho, M. Nafamostat mesylate in the prevention of post-ERCP pancreatitis and risk factors for post-ERCP pancreatitis. Gastrointest. Endosc.？2009, 69, e11–e18.
Xiping, Z.; Jie, Z.; Qin, X.; Guanghua, F.; Yang, C.; Tongfa, J.; Qi, X. Influence of baicalin and octreotide on NF-kappaB and p-selectin expression in liver and kidney of rats with severe acute pancreatitis. Inflammation？2009, 32, 1–11.
[46]
Sha, H.; Ma, Q.; Jha, R.K.; Xu, F.; Wang, L.; Wang, Z.; Zhao, Y.; Fan, F. Resveratrol ameliorates hepatic injury via the mitochondrial pathway in rats with severe acute pancreatitis. Eur. J. Pharmacol.？2008, 601, 136–142.
[47]
Xiping, Z.; Hua, T.; Hanqing, C.; Li, C.; Zhiwei, W.; Keyi, W.; Wei, Y.; Yun, L.; Qingyu, L.; Qing, H.; Fei, W. The protecting effects and mechanisms of Baicalin and Octreotide on heart injury in rats with SAP. Mediators Inflamm.？2007, 2007, 19469. 18274634
[48]
Barkay, O.; Niv, E.; Santo, E.; Bruck, R.; Hallak, A.; Konikoff, F.M. Low-dose heparin for the prevention of post-ERCP pancreatitis: A randomized placebo-controlled trial. Surg. Endosc.？2008, 22, 1971–1976.
[49]
Wang, L.; Ma, Q.; Chen, X.; Sha, H.; Ma, Z. Effects of resveratrol on calcium regulation in rats with severe acute pancreatitis. Eur. J. Pharmacol.？2008, 580, 271–276.
[50]
Cheng, B.Q.; Liu, C.T.; Li, W.J.; Fan, W.; Zhong, N.; Zhang, Y.; Jia, X.Q.; Zhang, S.Z. Ethyl pyruvate improves survival and ameliorates distant organ injury in rats with severe acute pancreatitis. Pancreas？2007, 35, 256–261.
[51]
Szabolcs, A.; Tiszlavicz, L.; Kaszaki, J.; Posa, A.; Berko, A.; Varga, I.S.; Boros, I.; Szuts, V.; Lonovics, J.; Takacs, T. Zerumbone exerts a beneficial effect on inflammatory parameters of cholecystokinin octapeptide-induced experimental pancreatitis but fails to improve histology. Pancreas？2007, 35, 249–255.
[52]
Zhang, X.P.; Zhang, L.; Yang, P.; Zhang, R.P.; Cheng, Q.H. Protective effects of baicalin and octreotide on multiple organ injury in severe acute pancreatitis. Dig. Dis. Sci.？2008, 53, 581–591.
[53]
Seo, S.W.; Jung, W.S.; Piao, T.G.; Hong, S.H.; Yun, K.J.; Park, R.K.; Shin, M.K.; Song, H.J.; Park, S.J. Selective cyclooxygenase-2 inhibitor ameliorates cholecystokinin-octapeptide-induced acute pancreatitis in rats. World J. Gastroenterol.？2007, 13, 2298–2304.
[54]
Xue, D.; Zhang, W.; Zhang, Y.; Wang, H.; Zheng, B.; Shi, X. Adjusting effects of baicalin for nuclear factor-kappaB and tumor necrosis factor-alpha on rats with caerulein-induced acute pancreatitis. Mediat. Inflamm.？2006, 5, 26295.
[55]
Zhao, H.; Lu, H.G.; Shi, Y.B.; Zhao, L.M.; Bai, C.; Wang, X. Role of enteral nutrition supplemented with ebselen and EHEC in pancreatitis-associated multiple organ dysfunction in rats. Inflamm. Res.？2006, 55, 423–429.
[56]
Kalyoncu, N.I.; Alhan, E.; Ercin, C.; Kural, B.V. Effects of dual inhibitor of cyclooxygenase and 5-lipoxygenase on acute necrotizing pancreatitis in rats. Hepatogastroenterology？2006, 53, 597–602.
[57]
Shapiro, H.; Singer, P.; Halpern, Z.; Bruck, R. Polyphenols in the treatment of inflammatory bowel disease and acute pancreatitis. Gut？2007, 56, 426–435.
[58]
de Almeida, J.L.; Jukemura, J.; Coelho, A.M.; Patzina, R.A.; Machado, M.C.; da Cunha, J.E. Inhibition of cyclooxygenase-2 in experimental severe acute pancreatitis. Clinics (Sao Paulo)？2006, 61, 301–306. 16924320
[59]
Alsfasser, G.; Warshaw, A.L.; Thayer, S.P.; Antoniu, B.; Laposata, M.; Lewandrowski, K.B.; Fernandez-del Castillo, C. Decreased inflammation and improved survival with recombinant human activated protein C treatment in experimental acute pancreatitis. Arch. Surg.？2006, 141, 670–676.
[60]
Lefter, L.P.; Dajbog, E.; Scripcariu, V.; Dragomir, C. Safety and efficacy of conservative management in acute severe pancreatitis. Chirurgia (Bucur.)？2006, 101, 135–139. 16752678
[61]
Cosen-Binker, L.I.; Binker, M.G.; Cosen, R.; Negri, G.; Tiscornia, O. Influence of nitric oxide-donating nonsteroidal anti-inflammatory drugs on the evolution of acute pancreatitis. Shock？2006, 25, 190–203.
[62]
Letoha, T.; Kusz, E.; Papai, G.; Szabolcs, A.; Kaszaki, J.; Varga, I.; Takacs, T.; Penke, B.; Duda, E. In vitro and in vivo nuclear factor-kappaB inhibitory effects of the cell-penetrating penetratin peptide. Mol. Pharmacol.？2006, 69, 2027–2036, doi:10.1124/mol.105.019653. 16505157
[63]
Ma, Z.H.; Ma, Q.Y.; Wang, L.C.; Sha, H.C.; Wu, S.L.; Zhang, M. Effect of resveratrol on peritoneal macrophages in rats with severe acute pancreatitis. Inflamm. Res.？2005, 54, 522–527.
[64]
Lau, H.Y.; Bhatia, M. The effect of CP96, 345 on the expression of tachykinins and neurokinin receptors in acute pancreatitis. J. Pathol.？2006, 208, 364–371.
[65]
Reding, T.; Bimmler, D.; Perren, A.; Sun, L.K.; Fortunato, F.; Storni, F.; Graf, R. A selective COX-2 inhibitor suppresses chronic pancreatitis in an animal model (WBN/Kob rats): Significant reduction of macrophage infiltration and fibrosis. Gut？2006, 55, 1165–1173.
[66]
Zhao, Y.F.; Zhai, W.L.; Zhang, S.J.; Chen, X.P. Protection effect of triptolide to liver injury in rats with severe acute pancreatitis. Hepatobiliary Pancreat. Dis. Int.？2005, 4, 604–608.
[67]
Alhan, E.; Kalyoncu, N.I.; Ercin, C.; Kural, B.V. Effects of the celecoxib on the acute necrotizing pancreatitis in rats. Inflammation？2004, 28, 303–309.
[68]
Huang, J.; Moochhala, S.M.; Moore, P.K.; Bhatia, M. Flurbiprofen and HCT1026 protect mice against acute pancreatitis-associated lung injury. Shock？2005, 24, 182–187.
[69]
Ma, Z.H.; Ma, Q.Y. Resveratrol: A medical drug for acute pancreatitis. World J. Gastroenterol.？2005, 11, 3171–3174.
[70]
Madanick, R.D.; O'Loughlin, C.J.; Barkin, J.S. Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography. Dig. Dis. Sci.？2005, 50, 879–881.
[71]
O'Brien, G.; Shields, C.J.; Winter, D.C.; Dillon, J.P.; Kirwan, W.O.; Redmond, H.P. Cyclooxygenase-2 plays a central role in the genesis of pancreatitis and associated lung injury. Hepatobiliary Pancreat. Dis. Int.？2005, 4, 126–128.
[72]
Meng, Y.; Zhang, M.; Xu, J.; Liu, X.M.; Ma, Q.Y. Effect of resveratrol on microcirculation disorder and lung injury following severe acute pancreatitis in rats. World J. Gastroenterol.？2005, 11, 433–435.
[73]
Yang, R.; Uchiyama, T.; Alber, S.M.; Han, X.; Watkins, S.K.; Delude, R.L.; Fink, M.P. Ethyl pyruvate ameliorates distant organ injury in a murine model of acute necrotizing pancreatitis. Crit. Care Med.？2004, 32, 1453–1459.
[74]
Slogoff, M.I.; Ethridge, R.T.; Rajaraman, S.; Evers, B.M. COX-2 inhibition results in alterations in nuclear factor (NF)-kappaB activation but not cytokine production in acute pancreatitis. J. Gastrointest. Surg.？2004, 8, 511–519.
[75]
Warzecha, Z.; Dembinski, A.; Ceranowicz, P.; Konturek, S.; Tomaszewska, R.; Stachura, J.; Nakamura, T.; Konturek, P.C. Inhibition of cyclooxygenase-2 reduces the protective effect of hepatocyte growth factor in experimental pancreatitis. Eur. J. Pharmacol.？2004, 486, 107–119.
[76]
Foitzik, T.; Hotz, H.G.; Hotz, B.; Wittig, F.; Buhr, H.J. Selective inhibition of cyclooxygenase-2 (COX-2) reduces prostaglandin E2 production and attenuates systemic disease sequelae in experimental pancreatitis. Hepatogastroenterology？2003, 50, 1159–1162.
[77]
Mentes, A.; Batur, Y.; Bayol, U. Salycylate--induced pancreatic injury in the cat: A preliminary study. Rom. J. Gastroenterol.？2002, 11, 309–312.
Hirata, M.; Hayashi, I.; Yoshimura, K.; Ishii, K.; Soma, K.; Ohwada, T.; Kakita, A.; Majima, M. Blockade of bradykinin B(2) receptor suppresses acute pancreatitis induced by obstruction of the pancreaticobiliary duct in rats. Br. J. Pharmacol.？2002, 135, 29–36.
[80]
Su, S.B.; Motoo, Y.; Xie, M.J.; Taga, H.; Sawabu, N. Antifibrotic effect of the herbal medicine Saiko-keishi-to (TJ-10) on chronic pancreatitis in the WBN/Kob rat. Pancreas？2001, 22, 8–17.
[81]
Su, S.B.; Motoo, Y.; Xie, M.J.; Sakai, J.; Taga, H.; Sawabu, N. Expression of pancreatitis-associated protein (PAP) in rat spontaneous chronic pancreatitis: Effect of herbal medicine Saiko-keishi-to (TJ-10). Pancreas？1999, 19, 239–247.
[82]
Andersen, V.; Sonne, J.; Larsen, S. Antipyrine, oxazepam, and indocyanine green clearance in patients with chronic pancreatitis and healthy subjects. Scand. J. Gastroenterol.？1999, 34, 813–817, doi:10.1080/003655299750025750. 10499483
[83]
Griesbacher, T.; Lembeck, F. Effects of the bradykinin antagonist, HOE 140, in experimental acute pancreatitis. Br. J. Pharmacol.？1992, 107, 356–360. 1384910
[84]
Henry, D.; Lim, L.L.; Garcia Rodriguez, L.A.; Perez Gutthann, S.; Carson, J.L.; Griffin, M.; Savage, R.; Logan, R.; Moride, Y.; Hawkey, C.; Hill, S.; Fries, J.T. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: Results of a collaborative meta-analysis. Br. Med. J.？1996, 312, 1563–1566.
[85]
Dai, H.F.; Wang, X.W.; Zhao, K. Role of nonsteroidal anti-inflammatory drugs in the prevention of post-ERCP pancreatitis: A meta-analysis. Hepatobiliary Pancreat. Dis. Int.？2009, 8, 11–16.
[86]
Elmunzer, B.J.; Waljee, A.K.; Elta, G.H.; Taylor, J.R.; Fehmi, S.M.; Higgins, P.D. A meta-analysis of rectal NSAIDs in the prevention of post-ERCP pancreatitis. Gut？2008, 57, 1262–1267.
[87]
Cheon, Y.K.; Cho, K.B.; Watkins, J.L.; McHenry, L.; Fogel, E.L.; Sherman, S.; Schmidt, S.; Lazzell-Pannell, L.; Lehman, G.A. Efficacy of diclofenac in the prevention of post-ERCP pancreatitis in predominantly high-risk patients: A randomized double-blind prospective trial. Gastrointest. Endosc.？2007, 66, 1126–1132.
[88]
Montano Loza, A.; Rodriguez Lomeli, X.; Garcia Correa, J.E.; Davalos Cobian, C.; Cervantes Guevara, G.; Medrano Munoz, F.; Fuentes Orozco, C.; Gonzalez Ojeda, A. Effect of the administration of rectal indomethacin on amylase serum levels after endoscopic retrograde cholangiopancreatography, and its impact on the development of secondary pancreatitis episodes. Rev. Esp. Enferm. Dig.？2007, 99, 330–335.
[89]
Khoshbaten, M.; Khorram, H.; Madad, L.; Ehsani Ardakani, M.J.; Farzin, H.; Zali, M.R. Role of diclofenac in reducing post-endoscopic retrograde cholangiopancreatography pancreatitis. J. Gastroenterol. Hepatol.？2008, 23, e11–e16.
[90]
Sotoudehmanesh, R.; Khatibian, M.; Kolahdoozan, S.; Ainechi, S.; Malboosbaf, R.; Nouraie, M. Indomethacin may reduce the incidence and severity of acute pancreatitis after ERCP. Am. J. Gastroenterol.？2007, 102, 978–983.
[91]
Peiro, A.M.; Martinez, J.; Martinez, E.; de Madaria, E.; Llorens, P.; Horga, J.F.; Perez-Mateo, M. Efficacy and tolerance of metamizole versus morphine for acute pancreatitis pain. Pancreatology？2008, 8, 25–29, doi:10.1159/000114852. 18235213
[92]
Sorensen, H.T.; Jacobsen, J.; Norgaard, M.; Pedersen, L.; Johnsen, S.P.; Baron, J.A. Newer cyclo-oxygenase-2 selective inhibitors, other non-steroidal anti-inflammatory drugs and the risk of acute pancreatitis. Aliment. Pharmacol. Ther.？2006, 24, 111–116.
[93]
Jick, H.; Derby, L.E.; Garcia Rodriguez, L.A.; Jick, S.S.; Dean, A.D. Nonsteroidal antiinflammatory drugs and certain rare, serious adverse events: A cohort study. Pharmacotherapy？1993, 13, 212–217.
[94]
Blomgren, K.B.; Sundstr？m, A.; Steineck, G.; Genell, S.; Sj？stedt, S.; Wiholm, B.E. A Swedish case-control network for studies of drug-induced morbidity: Acute pancreatitis. Eur. J. Clin. Pharmacol.？2002, 58, 275–283.
[95]
Ibá？ez, L.; Laporte, J.R.; Carné, X. Adverse drug reactions leading to hospital admission. Drug Saf.？1991, 6, 450–459.
[96]
Motola, D.; Vaccheri, A.; Silvani, M.C.; Poluzzi, E.; Bottoni, A.; De Ponti, F.; Montanaro, N. Pattern of NSAID use in the Italian general population: A questionnaire-based survey. Eur. J. Clin. Pharmacol.？2004, 60, 731–738.
[97]
Pezzilli, R.; Romboli, E.; Campana, D.; Corinaldesi, R. Mechanisms involved in the onset of post-ERCP pancreatitis. J.O.P.？2002, 3, 162–168.
[98]
Kunz, D.; Bank, U.; Ittenson, A.; Schulz, H.U.; Sokolowski, A. Alteration of immunological functions in acute pancreatitis. Eur. J. Clin. Chem. Clin. Biochem.？1993, 31, A35–A36.
[99]
Kiviniemi, H.; Juvonen, T.; Makela, J. Acute phase response in patients with uncomplicated endoscopic retrograde cholangiopancreatography. H.P.B. Surg.？1994, 8, 129–131.
[100]
Oezcueruemez-Porsch, M.; Kunz, D.; Hardt, P.D.; Fadgyas, T.; Kress, O.; Schulz, H.U.; Schnell-Kretschmer, H.; Temme, H.; Westphal, S.; Luley, C.; Kloer, H.U. Diagnostic relevance of interleukin pattern, acute-phase proteins, and procalcitoninin early phase of post-ERCP pancreatitis. Dig. Dis. Sci.？1998, 43, 1763–1769. 9724166
[101]
Kaw, M.; Singh, S. Serum lipase, C-reactive protein, and interleukin-6 levels in ERCP-induced pancreatitis. Gastrointest. Endosc.？2001, 54, 435–440, doi:10.1067/mge.2001.117763. 11577303
[102]
Blanchard, J.A.; Barve, S.; Joshi-Barve, S.; Talwalker, R.; Gates, L.K. Cytokine production by CAPAN-1 and CAPAN-2 cell lines. Dig. Dis. Sci.？2000, 45, 927–932.
[103]
Pezzilli, R.; Gabbrielli, A.; Morselli-Labate, A.M.; D'Alessio, P.; Barakat, B.; Costamagna, G.; Dibenedetti, F.; Massa, M.; Merlini, G.; Melzi d'Eril, G.M. Does gabexate mesilate affect serum concentrations of acute phase proteins after endoscopic retrograde cholangiopancreatography examination? Hepatogastroenterology？2003, 50, 851–855. 12828103
[104]
Deviere, J.; Le Moine, O.; Van Laethem, J.L.; Eisendrath, P.; Ghilain, A.; Severs, N.; Cohard, M. Interleukin 10 reduces the incidence of pancreatitis after therapeutic endoscopic retrograde cholangiopancreatography. Gastroenterology？2001, 120, 498–505.
[105]
Sherman, S.; Cheng, C.L.; Costamagna, G.; Binmoeller, K.F.; Puespoek, A.; Aithal, G.P.; Kozarek, R.A.; Chen, Y.K.; Van Steenbergen, W.; Tenner, S.; Freeman, M.; Monroe, P.; Geffner, M.; Deviere, J. Interleukin-10 ERCP Study Group. Efficacy of recombinant human interleukin-10 in prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis in subjects with increased risk. Pancreas？2009, 38, 267–274. 19214137
[106]
Gross, V.; Leser, H.G.; Heinisch, A.; Sch？lmerich, J. Inflammatory mediators and cytokines. New aspects of pathophysiology and assessment of severity of acute pancreatitis? Hepatogastroenterology？1993, 40, 522–530. 7509768
[107]
Makela, A.; Kuusi, T.; Schroeder, T. Inhibition of serum phospholipase A2 in acute pancreatitis by pharamacologic agents in vitro. Scand. J. Clin. Lab. Invest.？1997, 57, 401–408, doi:10.3109/00365519709084587. 9279965
[108]
Davies, N.M.; Anderson, K.E. Clinical phamacokinetics of diclofenac. Therapeutic insights and pitfalls. Clin. Pharamakokinet.？1997, 33, 184–213, doi:10.2165/00003088-199733030-00003.
[109]
Pezzilli, R. Pharmacotherapy for acute pancreatitis. Expert Opin. Pharmacother.？2009, 10, 2999–3014.
Ferreira, S.H.; Vane, J.R. New aspects of the mode of action of nonsteroidal anti-inflammatory drugs. Annu. Rev. Pharmacol.？1974, 53, 57–73.
[112]
Swift, J.Q.; Garry, M.G.; Roszkowski, M.T.; Hargreaves, K.M. Effect of flurbiprofen on tissue levels of immunoreactive bradykinin and acute post-operative pain. J. Oral. Maxillofac. Surg.？1993, 51, 112–116.
[113]
Cashman, J.N. The mechanisms of action of NSAIDs in analgesia. Drugs？1996, 5, 13–23.
[114]
Malmberg, A.B.; Yaksh, T.L. Hyperalgesia mediated by spinal glutamate or substance P receptor blocked by spinal cyclooxygenase inhibition. Science？1992, 257, 1276–1279.
[115]
Pezzilli, R.; Uomo, G.; Gabbrielli, A.; Zerbi, A.; Frulloni, L.; De Rai, P.; Castoldi, L.; Cavallini, G.; Di Carlo, V. ProInf-AISP Study Group. A prospective multicentre survey on the treatment of acute pancreatitis in Italy. Dig. Liver Dis.？2007, 39, 838–846, doi:10.1016/j.dld.2007.05.014. 17602904
